Diagnosing Lysosomal Storage Disorders: The GM2 Gangliosidoses
- PMID: 25271840
- DOI: 10.1002/0471142905.hg1716s83
Diagnosing Lysosomal Storage Disorders: The GM2 Gangliosidoses
Abstract
The GM2 gangliosidoses are a group of autosomal recessive lysosomal storage disorders caused by defective β-hexosaminidase. There are three clinical conditions in this group: Tay-Sachs disease (TSD), Sandhoff disease (SD), and hexosaminidase activator deficiency. The three conditions are clinically indistinguishable. TSD and SD have been identified with infantile, juvenile, and adult onset forms. The activator deficiency is only known to present with infantile onset. Diagnosis of TSD and SD is based on decreased hexosaminidase activity and a change in the percentage of activity between isoforms. There are no biochemical tests currently available for activator deficiency. This unit provides a detailed procedure for identifying TSD and SD in affected individuals and carriers from leukocyte samples, the most robust sample type available.
Keywords: GM2 gangliosidosis; Sandhoff disease; Tay-Sachs disease; hexosaminidase.
Copyright © 2014 John Wiley & Sons, Inc.
Similar articles
-
The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.Pediatrics. 2006 Nov;118(5):e1550-62. doi: 10.1542/peds.2006-0588. Epub 2006 Oct 2. Pediatrics. 2006. PMID: 17015493 Free PMC article. Review.
-
Plasma GM2 ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis.Mol Genet Metab. 2023 Feb;138(2):106983. doi: 10.1016/j.ymgme.2022.106983. Epub 2022 Dec 26. Mol Genet Metab. 2023. PMID: 36709536
-
[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].Yakugaku Zasshi. 2013;133(2):269-74. doi: 10.1248/yakushi.12-00199. Yakugaku Zasshi. 2013. PMID: 23370522 Review. Japanese.
-
Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.Biochem Biophys Rep. 2016 Jun 8;7:157-163. doi: 10.1016/j.bbrep.2016.04.012. eCollection 2016 Sep. Biochem Biophys Rep. 2016. PMID: 28955902 Free PMC article.
-
GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.Gene. 2012 Sep 10;506(1):25-30. doi: 10.1016/j.gene.2012.06.080. Epub 2012 Jul 10. Gene. 2012. PMID: 22789865
Cited by
-
Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy.Int J Mol Sci. 2019 Nov 24;20(23):5897. doi: 10.3390/ijms20235897. Int J Mol Sci. 2019. PMID: 31771289 Free PMC article. Review.
-
GM2 Activator Deficiency Caused by a Homozygous Exon 2 Deletion in GM2A.JIMD Rep. 2018;38:61-65. doi: 10.1007/8904_2017_31. Epub 2017 May 25. JIMD Rep. 2018. PMID: 28540636 Free PMC article.
-
Essential laboratory tests for medical education.Acad Pathol. 2022 Sep 13;9(1):100046. doi: 10.1016/j.acpath.2022.100046. eCollection 2022. Acad Pathol. 2022. PMID: 36133797 Free PMC article.
-
An Infantile Case of Sandhoff Disease Presenting With Swallowing Difficulty.Ann Rehabil Med. 2017 Oct;41(5):892-896. doi: 10.5535/arm.2017.41.5.892. Epub 2017 Oct 31. Ann Rehabil Med. 2017. PMID: 29201831 Free PMC article.
-
Therapeutic Strategies For Tay-Sachs Disease.Front Pharmacol. 2022 Jul 5;13:906647. doi: 10.3389/fphar.2022.906647. eCollection 2022. Front Pharmacol. 2022. PMID: 35865957 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
